reviewDrug Design Development and TherapyAug 1, 2015GOLD OA

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

MLMichael LahnSHStephan HerbertzJSJ. Scott SawyerAJAnja J. StauberIGIvelina Gueorguieva

Eli Lilly (United States) · Eli Lilly (Germany) · +1 more institution

Indexed incrossrefdoaj

Abstract

Keywords: TGF-β, TGF-βRI kinase inhibitor, ALK5, galunisertib, LY2157299, cancer, clinical trials

Citation impact

543
total citations
FWCI
21.53
Percentile
100%
References
178
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Medicine
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Cancer
  • Cancer research
  • Sorafenib
  • Hepatocellular carcinoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.